224O - Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

M.l Friedlander ,S Banerjee,A Floquet ,G.s Sonke ,G Scambia ,K.n Moore ,A Oaknin ,B.-G Kim ,N Colombo ,A González-Martín ,C Gourley ,E Flood ,E Lowe ,R Hettle ,W Bradley ,A Leary ,C Aghajanian ,A Lisyanskaya ,A Oza ,P Disilvestro

doi:10.1093/annonc/mdz426

224O - Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

M.l Friedlander , S Banerjee + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz426

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2019
License type: publisher-specific-oa

#Clovis Oncology #Quality-adjusted Progression-free Survival + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

224O - Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

Full Text